Pasithea Therapeutics Corp. (KTTA) has received a notice from Nasdaq regarding its failure to meet the $1.00 minimum bid price requirement, as its stock traded below this threshold for 30 consecutive business days. The company has 180 calendar days, until August 19, 2026, to regain compliance by achieving a closing bid of at least $1.00 for ten straight business days, with a possible extension. Despite the notice, KTTA’s listing status and business operations remain unaffected for now, and the company is evaluating its options to restore compliance.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice
Pasithea Therapeutics Corp. (KTTA) has received a notice from Nasdaq regarding its failure to meet the $1.00 minimum bid price requirement, as its stock traded below this threshold for 30 consecutive business days. The company has 180 calendar days, until August 19, 2026, to regain compliance by achieving a closing bid of at least $1.00 for ten straight business days, with a possible extension. Despite the notice, KTTA’s listing status and business operations remain unaffected for now, and the company is evaluating its options to restore compliance.